Related Experiment Videos
Endothelin, vascular hypertrophy, and hypertension
1Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Cardiovascular Drugs and Therapy
|January 1, 1997
Summary
Endothelins (ET) are peptides impacting blood vessel constriction and growth. While ET plays a role in hypertension-related vascular hypertrophy in animal models, its role in human hypertension requires further investigation with new antagonists.
Area of Science:
- Cardiovascular Biology
- Endocrinology
- Pharmacology
Background:
- Endothelins (ET-1, ET-2, ET-3) are 21-amino-acid peptides with significant biological activities.
- They are produced in various tissues, including vascular endothelium and smooth muscle cells, with production stimulated by diverse factors like hypoxia and growth factors.
- Released endothelin interacts with ETA and ETB receptors, mediating vasoconstriction and nitric oxide release, respectively.
Purpose of the Study:
- To explore the role of endothelin in vascular hypertrophy within the context of hypertension.
- To review the complex interplay of factors involved in the pathogenesis of vascular hypertrophy.
- To assess the current evidence for endothelin's involvement in human hypertension and discuss future research directions.
Main Methods:
- Review of existing literature on endothelin's biological activities and receptor interactions.
- Analysis of findings from animal models of hypertension (DOCA-salt rat, spontaneously hypertensive rat).
- Examination of human studies investigating plasma endothelin concentrations in hypertension and atherosclerotic disease.
Main Results:
- Endothelin binding to ETA receptors activates signaling pathways leading to vasoconstriction and vascular smooth muscle cell proliferation.
- Animal models demonstrate endothelin-induced vascular hypertrophy, with varying degrees depending on the hypertension model.
- Elevated plasma endothelin is observed in severe atherosclerosis but not consistently in hypertension; evidence for its role in human hypertension-induced vascular hypertrophy is limited.
Conclusions:
- Endothelin signaling is implicated in vascular hypertrophy, particularly in animal models of hypertension.
- Further research, facilitated by new receptor antagonists, is needed to clarify endothelin's precise role in human hypertension.
- Development of selective endothelin receptor antagonists may lead to novel antihypertensive therapies.